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Two cold-recombinant influenza A (HI N 1) viruses were tested in several 
groups of human volunteers. Only minor clinical symptoms were seen and no 
febrile reactions occurred. With serologically primed individuals virus shed- 
ding was low, but a high proportion showed rises in serum antibody levels 
after vaccination and mean titres were high. With serologically unprimed 
volunteers shedding was high, about 75% yielding viruses but only at low 
titres and for a short duration. No revertant viruses were found and there was 
no evidence of transmission to  potentially susceptible individuals housed in 
close contact to the vaccinees. 
Serum antibody responses with unprimed volunteers were, however, low. 
Only about one half showed increases in serum antibody titres after vaccina- 
tion and mean titres were low. Nevertheless, challenge with live attenuated 
virus indicated a high degree of protection based on virological evidence of 
infection. 
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Previous studies [Maassab et al, 1972; Maassab et al, 1977; Maassab, 19751 have 
shown that the cold-adapted influenza A virus, A/AA/6/60 (H2N2) [Maassab, 1967; 
Kitayama et al, 19731 can be used to generate attenuated recombinant viruses for use as 
live-virus vaccine strains. We have described clinical trials in adults and children with a 
live-virus vaccine containing an A/Victoria/3/75 (H3N2) cold-recombinant virus. CR22 
[Moritz et al, 19781. With this recombinant reactogcnicity was slight and serum antibody 
responses good, a high proportion of volunteers showing serum conversion. 
Mean serum titres after vaccination with the live vaccine were high in accordance 
with the findings of others employing attenuated H3N2 influenza A virus recombinants 
[Huygelen et al, 1973; Hrabar et al, 1977; Murphy et al, 1978; Moffat et al, 1976; Rubin 
et al, 19761 . Studies with H3N2 viruses have all been made during the A/Hong Kong/78 
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(H3N2) influenza drift period. All volunteer studies, therefore, would have been made 
with persons who were likely to have had previous infection with H3N2 viruses. Thus, 
even volunteers without detectable antibody to the A/Victoria/3/75 (H3N2) virus are 
likely to have been primed immunologically to H3N2 subtype viruses. Priming might have 
mediated the clinical response to live-virus vaccination, for example, by ameliorating re- 
sidual virulence of an apparently attenuated strain. The serological responses seen might 
also have resulted from an amnestic response to previously encountered antigens. It was 
of great interest, therefore, to study the clinical and immunological responses to H l N l  
virus recombinants. As strains of this subtype had not been epidemic since 1956, a sub- 
stantial population of young adults existed with no  previous exposure to such viruses. 
They would, therefore, be immunologically unprotected. Indeed, substantial outbreaks of 
influenza were reported in children and young adults between 1978 and 1979 [Zhadnov 
et al, 1978; Gregg et al, 19781. We describe here the clinical, virological, and serological 
responses found in both primed and unprimed volunteers to two H l N l  cold-recombinant 
influenza viruses. We also show from subsequent challenge infections that such live-virus 
vaccination induces substantial protection for up to at least five months. 
MATERIALS AND METHODS 
Viruses 
The origin and properties of the two viruses, recombinant CR33 and recombinant 
BG12, will be described [Reeve et al, unpublished information]. The CR33 recombinant 
was derived by Professor Maassab in his laboratory in Michigan, by recombination be- 
tween the A/AA/6/60 (H2N2) cold-adapted virus and the A/USSR/90/77 (HlNl)  virus. 
This work was supported by the US government NAIAD contract No. 1-A1-72521. 
Subsequent preclinical and clinical studies with CR33 were performed at the Sandoz 
Research Institute, Vienna. The other recombinant, BG12, was derived in our labora- 
tories by recombination between the A/AA/6/60 (H2N2) cold-adapted virus and the 
A/USSR/92/77 (HlN1) virus. The genes coding for HA, NA, and one of the P proteins of 
virus BG12 are derived from the wild-type virus. In the case of the CR33, only the genes 
coding for the surface antigens haemagglutinin (HA) and neuraminidase (NA) derive from 
the wild-type virus. 
Volunteers 
Volunteers for two studies were recruited from seronegative male or female univer- 
sity students aged 19 to 26 years who had given informed consent. Seronegative subjects 
were selected where serum haemagglutination inhibition (111) and serum neuraniinidase 
inhibition (NI) titres were < 1:8 using an A/USSR/92/77 (HlN1) antigen. Pregnancy, 
current or recent upper respiratory tract infections, and known sensitivity to  egg proteins 
were grounds for exclusion of volunteers from the study, The volunteers were given the 
following medical and clinical laboratory exaniinations before admission to the studies 
and excluded if abnormalities were detected: complete blood counts, chest X ray, blood 
chemistry (BUN, SGOT, SGPT, alkaline phosphatase, bilirubin, and fasting glucose levels), 
patellar tendon reflexes, and urinalysis. They were lodged at a sequestered wing of an 
hotel in the Vienna Woods in double and single rooms and so separated from the public. 
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In a third trial, volunteers aged 30 to  46 years were eniployees of the Sandoz Research 
Institute. 
Volunteer studies conformed to  the guidelines for human experimentation, 
Declaration of Helsinki, and had received institutional and ethcal approval. 
tnitial Studies 
Three clinical trials have been made with adult Volunteers. In two, volunteers were 
selected with no  detectable serum HI, NI, or serum neutralising (SN) antibodies. Older 
volunteers (aged 30 years or more) participated in a trial concurrent with the second 
study, some possessing HI antibody. It is very likely that those older volunteers would 
have been “primed” to H l N l  subtype viruses by previous exposure before 1956. The 
trials were made in the Autumn of 1978. At this time there were no current epidemics of 
respiratory disease in Vienna. 
Serum samples collected immediately before vaccination and three weeks there. 
after, were assayed for HI or NI using techniques described [Kunz et al, 19771 and an 
A/USSR/92/77 (HlN1) antigen. SN antibodies were assayed using a plaque reduction 
assay and virus A/USSR/92/77 (HINl). 
Challenge Studies 
Volunteers from the previous trials with young volunteers were asked to take part 
in a further trial in which their resistance to infection with the recombinant BG12 was 
tested. Challenge studies were made four months and five months, respectively, after the 
original vaccination studies. An additional age-matched unimmunised group was also 
included. A total of 52 volunteers were included in this study. All volunteers received 6.4 
(log,,) EIDso while the volunteer remained prone, head tilted back, for approximately 
one minute. Subsequently, every day for four days nasal swabs were obtained for virus- 
isolation studies. Three weeks after the start of the challenge trial a further serum sample 
was taken for antibody determinations. 
minimal essential medium (MEM) containing 10% (v/v) tryptose phosphate broth as 
transport medium. On the same day of collection, swab material was inoculated into 
Madin Derby Canine Kidney (MDCK) cell cultures in the presence of MEM with 10 
pgrn/ml trypsin for virus isolation [Oxford et al, 19791. 
Virus isolations were made from material collected by nasal swabs using Eagle’s 
RESULTS 
Trials in Young Seronegative Adult Volunteers 
In both trials volunteers were inoculated intranasally with either recombinant 
CR33, recombinant BG12, or physiological saline. Inoculations were given in 0.4-ml 
volumes according to a computer-generated randomisation list. 
In the second trial a hglier dosage was given and volunteers received either 8.6 (loglo) 
EIDSO, recombinant BG12 or 8.7 (loglo) ED5* recombinant CR33, or placebo. 
Clinical Reactions After Vaccination 
All reactions to vaccine or placebo were mild (Table I). The most frequently ob- 
served reactions to live-virus vaccine were slight “stuffy nose” or “running nose.” With 
the first study five of 12 volunteers given recombinant CR33 and three of 12 given re- 
In the first trial, volunteers received 7.4 (log, ,) EID, of virus vaccine or placebo. 
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TABLE 1. Clinical Responses of Young Adult Volunteers to Influenza A (HINI) Recombinant 
Viruses* 
Dose 
(loglo) No. of No. with No. with afebrile No. with upper 
Study No. Vaccine EID, , volunteers fever systemic reactions respiratory symptoms 
1 Placebo 0 13 0 1 
BG12 7.4 12 1 5 
CR33 7.4 13 0 3 
2 Placebo 0 7 0 0 
BG12 8.6 7 0 5 
CR33 8.7 7 0 3 
*Fever was regarded as an oral temperature of 38OC or higher. Systemic reactions, headache, fatigue, 
muscular pains or weakness, were included when recorded as “moderate” on any one occasion or 
“slight” on at least two consecutive days. No “severe” reactions were seen. Upper respiratory tract 
reactions, cough, sore throat, stuffy or running nose are included using the same criteria. 
combinant BG12 reported stuffy or running noses. One volunteer given recombinant 
CR33 reported a running nose, slight cough, and headache and one a stuffy nose and 
myalgia. A further volunteer given recombinant CR33 complained of headache and a 
running nose on the day of inoculation. With recombinant BG12 two volunteers with 
running noses complained of slight or moderate headaches. In this study five of 12 volun- 
teers given placebo also complained of slight running or stuffy noses, two had coughs, 
and one a moderate headache. 
In our second study with young volunteers a similar picture was seen. With re- 
combinant CR22 three of seven had running or stuffy noses; with recombinant BG12 
three of eight had running or stuffy noses and two in addition complained o f  slight sore 
throats. In this study no reactions were observed from the placebo group (Table I). 
Two volunteers who had received recombinant BG12 showed transitory rises in 
body temperature on the second day after inoculation. The maximum recorded temper- 
ature being 38.9”C with one volunteer and 38.0”C with the other. All other volunteers 
recorded normal body temperatures. 
(Table 11). No viruses were isolated from the placebo groups, and no revertant viruses 
were found. It was evident from the virus isolations that most volunteers were infected 
with the live-recombinant viruses. 
The serum antibody responses were low. Only a proportion of the volunteers 
showed increases in serum titres whether measured in the HI, NI, or SN tests. Increasing 
the dose inoculated did not markedly increase the number of volunteers showing serocon- 
version (Table 11). The overall percentage of volunteers showing increases in serum titres 
was approximately 50% and the mean serum HI titre was 1 : 12 (Table 11). 
A high proportion of volunteers shed viruses for up to seven days after inoculation 
Effect of Second Vaccination 
prompted us to reinoculate the volunteers with one of several preparations. Firstly, we 
considered whether the low titres found were merely a response to the antigenic mass of 
The finding of low rates of seroconversion and low mean serum antibody titres 
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TABLE 11. Response to  Intranasal Infection With Cold-Recombinant Influenza A (HlN1) Viruses' 
Dose Serum HI responses 
(1% 1 0) No. of No. with reciprocal titres of No. shedding 
Study No. Vaccine EID,, Volunteers <8 8 16 >16 virus 
1 Placebo 0 13 1 1 2 0 0  0 
BG12 7.4 12 3 6 3 0  10 
CR3 3 7.4 13 3 6 3 l ( 3 2 )  10 
2 Placebo 0 I 6 1 0 0  0 
BG12 8.6 8 3 3 1 l (512)  6 
CR3 3 8.7 I 2 3 1 1 (32) 3 
*Seronegative volunteers under 20 years old were inoculated with either a recombinant virus or 
placebo in double-blind closed trials. Serum haemagglutination inhibition (HI) responses were mea- 
sured to homologous antigens three weeks after infection. Before immunisation all volunteers had HI 
titres of < 1 :8. Virus isolations were made from nasal swabs using MDCK cell cultures and Eagle's 
minimal essential medium containing 10 /.fgm/ml trypsin. 
the locally applied virus. Accordingly, a group of volunteers previously inoculated with 
placebo material and a further group who had received live-recombinant BG 12 were re- 
inoculated by the intranasal route with a formalin-inactivated preparation of the recombi- 
nant BG12. None of the volunteers from either group showed a change in serum antibody 
titres, Table 111. From this we concluded that the responses found were not due merely 
to the antigenic mass of the live-virus preparations. This experiment also showed that no 
booster type of response could be elicitated using killed vaccine intranasally. Volunteers 
from the group which had received recombinant CR33 were revaccinated with the sub- 
unit vaccine Sandovac@ [Bachmayer et al, 1976; Kunz et al, 19771 containing 10 pg  
A/USSR/90/77 (HlNl)  per dose. After the booster immunization with SandovacO one 
half (55%) of the volunteers showed rises in serum HI titres and the GMT was 1:20, 
Table 111. This response was not significantly higher than the response of unprimed indi- 
viduals to a single dose of the subunit vaccine. In another attempt to boost antibody 
responses, all of the volunteers from study No. 2 were inoculated intranasally with 
8.1 (log,,) EID,, recombinant BG12. The changes in serum titres observed did not 
differ from the immune response observed after the first dose of the vaccine (Table 111). 
Trial in Volunteers "Primed" Against H lN l  Influenza 
To test the response to live vaccination with H l N l  influenza A viruses in primed 
individuals, eight volunteers over 30 years old were inoculated intranasally with 8.1 
(log, o )  EID, of the recombinant BG12. 
Four of the volunteers possessed initial titres of 1 :8 or less: All showed twofold 
or greater rises in serum HI titres 38 days after vaccination. The mean titres were 1 :22. 
The remaining four volunteers possessed initial titres of 1 : 16 or more. None showed sig- 
nificant rises in serum HI titres (Table IV). 
Challenge Trial 
From the control group of 11 unimmunised volunteers, seven shed viruses up to 
four days aftcr infection. The maximum titre found was 4.0 (logl ,) TCID, and the 
mean was 2.5 (log, o )  TCID, (Table V). 
80 Reeve et a1 
TABLE 111. Response to Reimmunisation With Live or Inactivated Cold-Recombinant Virus Given 
Intranasally or Parenterai Subunit Vaccine* 
Serum HI responses 
following booster vaccine 
First Booster No. of Percentage showing any Reciprocal 
Study No. Vaccinea Vaccinea vvlunteers serum titre increases mean titres 
1 Placebo Inactivated 8 
BG12 
BG12 Inactivated 1 2  
BG12 
CR33 Sandovac@ 11 
2 Placebo BG12 7 
BG12 BG12 5 













vaccines administered intranasally. Only Sandovac given IM/SC. 
*Volunteers from previous studies (Table I) were reimmunised with the preparation indicated. 
Volunteers in study No. 2 received 8.1 (loglo) EID,, recombinant BG12 as a booster inocula- 
tion. Serum haemagglutination inhibition (HI) responses were measured using homologous 
antigens three weeks after booster inoculation. 
TABLE IV. Response of ‘‘Primed’’ Individuals t o  Intranasal Infection With a Cold-Recombinant 
Influenza A (HlNI)  Virus* 
Reciprocal serum HI titre 
Volunteer No. Before vaccination After vaccination 
Volunteers with HI titres o f  30 




Volunteers with HI titres of 


























*Volunteers over 30 years old were infected with 8.1 (log, o) EID,, of the recombinant BG12. Serum 
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A similar shedding pattern was found with the ten volunteers given placebo in a 
first trial made five months before the challenge study. Six of the ten shed viruses for as long 
as four days. The maximum titre was 4.0 (log, o )  TCIDS , and the mean was 2.2 (log,,) 
TCLD, , (Table V). The overall infection rate of both “unprotected” groups was 64%. 
From the volunteers previously vaccinated with recombinant BGl2, CR33, or both 
viruses, only three virus isolations were obtained from a total number of 30 volunteers 
(Table V). Thus, previous vaccination with live-virus vaccine induced a highly significant 
degree of protection in comparison with the control groups @ < 0.001). The numbers of 
volunteers in each group was small and so it is not possible to compare the efficacy of 
the different vaccination schedules used. But there was no major difference between vol- 
unteers immunized four months or five months before challenge. The viruses reisolated 
proved antigenically identical to A/USSR/92/77 (HlN1) in HI tests. 
DISCUSSION 
When young double-seronegative and “unprimed” volunteers were infected with 
cold-recombinant influenza A viruses of the subtype HlN1, a high proportion were in- 
fected as judged from virus shedding. Despite prolonged virus shedding, serum antibody 
responses were poor. Only a proportion showed changes in serum HI or SN titres and 
mean titres were low. We concluded that the serological response which we could detect 
was due to infection since intranasal administration of homologous-killed antigen to 
unimmunised volunteers did not induce any immune response at all. We could not boost 
the immune response to H l N l  viruses after vaccination with live, attenuated viruses by 
killed-virus antigen applied intranasally or by subsequent intranasal inoculation with live, 
attenuated virus. 
The poor immune response was not due, however, to a defect in the antigenicity of 
the recombinants. Both induced, high titres of circulatory antibody in hamsters infected 
intranasally [Reeve et al, unpublished information] . Additionally, good immune re- 
sponses were seen in the volunteers from the higher age group where the response was 
similar to that found with a cold-recombinant H3N2 influenza virus [Moritz et al, 19781 . 
The serum antibody levels found in the younger volunteers would give no evidence 
of protection against infection with homologous virus. Hobson [Hobson et al, 19721 
from a challenge study of volunteers previously immunized with a killed-influenza 
(H3N2) vaccine estimated the 50% protective antibody level to be 1 :36. In our studies 
with live H l N l  influenza virus vaccines in unprimed persons, such serum HI titres were 
not achieved even after booster vaccinations. We could not, therefore, conclude from 
serological results that vaccination of unprimed persons with the live H l N l  vaccines 
would confer protection against reinfection. A challenge study, however, using live at- 
tenuated virus subsequently demonstrated a highly significant degree of protection four 
and five months after vaccination. 
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